Your browser doesn't support javascript.
loading
Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén, Milana Bergamino; Fernández-Ortega, Adela; Stradella, Agostina; Morilla, Idoia; Falo, Catalina; Vázquez, Silvia; Castany, Roser; Villanueva, Rafael; Recalde, Sabela; Pérez, Valentí Navarro; Gil-Gil, Miguel; Pernas, Sonia.
Afiliação
  • Sirvén MB; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Fernández-Ortega A; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Stradella A; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Morilla I; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Falo C; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Vázquez S; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Castany R; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Villanueva R; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Recalde S; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Pérez VN; Research Unit, Institut Català d'Oncologia-(ICO) L'Hospitalet, Barcelona, Spain.
  • Gil-Gil M; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain.
  • Pernas S; Department of Medical Oncology-Breast Cancer Unit, Insitut Catala d'Oncologia (ICO)-H.U.Bellvitge- IDIBELL, Avinguda Gran Via 199-203, 08908-L'Hospitalet de Llobregat, Barcelona, Spain. spernas@iconcologia.net.
BMC Pharmacol Toxicol ; 20(1): 68, 2019 11 21.
Article em En | MEDLINE | ID: mdl-31753013
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Furanos / Cetonas / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans País/Região como assunto: Europa Idioma: En Revista: BMC Pharmacol Toxicol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Furanos / Cetonas / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans País/Região como assunto: Europa Idioma: En Revista: BMC Pharmacol Toxicol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha